44 Wealth Management LLC Has $3.13 Million Position in Bristol Myers Squibb Company $BMY

44 Wealth Management LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 12.7% in the fourth quarter, Holdings Channel reports. The firm owned 58,080 shares of the biopharmaceutical company’s stock after selling 8,482 shares during the period. Bristol Myers Squibb accounts for 1.0% of 44 Wealth Management LLC’s investment portfolio, making the stock its 16th biggest holding. 44 Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $3,133,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb in the third quarter valued at approximately $35,000. Finally, Garner Asset Management Corp acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Cantor Fitzgerald upped their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. UBS Group reissued a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Finally, HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $59.51 on Monday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a fifty day simple moving average of $58.46 and a 200 day simple moving average of $55.92. The stock has a market capitalization of $121.51 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.